Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Experimental Drug Blocks Development of Malignant Melanomas

By LabMedica International staff writers
Posted on 14 Feb 2019
A promising experimental drug may prevent growth and spread of malignant melanomas having a mutation in the NRAS gene.

Activating mutations in the NRAS (Neuroblastoma RAS viral oncogene homolog) gene account for 20%–30% of melanoma, but despite decades of research no effective anti-NRAS therapies have been developed.

With this in mind, investigators at Boston University School of Medicine (MA, USA) identified the previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. More...
The protein encoded by STK19 localizes predominantly to the nucleus. Its specific function is unknown, but it is thought that phosphorylation of this protein may be involved in transcriptional regulation.

The investigators reported in the January 31, 2019, online edition of the journal Cell that STK19 phosphorylated NRAS, which enhanced its binding to its downstream effectors and promoted oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N (aspartate (D89) to aspargine) substitution in STK19 - whose alterations were identified in 25% of human melanomas - represented a gain-of-function mutation that interacted better with NRAS to enhance melanocyte transformation. STK19 D89N activation led to skin hyperpigmentation and promoted NRAS-driven melanoma formation in vivo.

In addition, the investigators described the development of the drug ZT-12-037-01 as a specific STK19-targeted inhibitor and showed that it effectively blocked oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo.

"This study provides a promising therapeutic strategy for melanoma treatment. Furthermore, the STK19 inhibitor might be a therapeutic option in 25% of all cancers with RAS mutations," said senior author Dr. Rutao Cui, professor of pharmacology and experimental therapeutics at Boston University School of Medicine. "We hope our findings ultimately will be clinically translated into improved care for cancer patients."

Related Links:
Boston University School of Medicine


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.